Q4 2025 OC, EC, & Pan-Tumor Market: Advancing Treatment Strategies with New Data, Simplified Dosing, and Clinical Developments 

A trial from the DESTINY clinical trial program was initiated to evaluate an Enhertu-based regimen in earlier lines of therapy for ovarian cancer.

Clinical developments building on Lynparza’s established foundation were presented, and educational DTC content on HRD testing was promoted.

Pharma& announced that new long-term data on Rubraca for ovarian cancer would be presented at a conference and positioned the brand as a central oncology asset for the company.

Zejula was differentiated within its mechanism of action, highlighting significant, durable efficacy and convenient dosing.

The approval of Keytruda Qlex was promoted, focusing on its streamlined administration and dosing options.

Landmark follow-up data reinforced the survival benefit of Keytruda + Lenvima in endometrial cancer. Eisai shared its latest research for the duo in multiple treatment settings and raised consumer awareness of endometrial cancer.

TESARO, a subsidiary of GSK, initiated litigation over the dostarlimab license agreement with AnaptysBio.